Introduction
A central question in vaccine design is how to trigger a broad but specific immune response against a pathogen or a tumour antigen. In general, an efficient immune response is dependent on the contributions from B-cells, CD8
þ and CD4
þ T-cells. CD4 þ T-cells are important for interferon (IFN)-g production and Ab formation, as well as long-term maintenance of CD8 þ memory cells. Furthermore, CD4
þ T-cells may exert cytolytic activity on MHC class II bearing target cells (Tite and Janeway, 1984; Bogen et al., 1986) . It is therefore important to increase our understanding of how CD4 þ T-cell function may be improved. Targeting of whole antigen or antigenic peptides to antigen presenting cells (APCs) by way of APC-specific Abs improves MHC class II peptide loading and specific CD4 þ T-cell activation, and both chemical conjugation (Carayanniotis and Barber, 1987; Snider and Segal, 1987) and genetic linking (Baier et al., 1995; Lunde et al., 1999; Hawiger et al., 2001 ) of antigen to Ab have been described. Abs are stable multi-domain proteins, and each Ab domain shares a characteristic structure, the Ig fold, consisting of anti-parallel b-strands that form two b-sheets stabilized by a conserved disulphide bond. The b-strands, A -F, are connected by loops, and six such loops exist in each of C H 1, C H 2 and C H 3 domains. These are numbered 1 -6, starting from the N-terminal end of each domain (Fig. 1A ).
We have previously described an approach where we substitute loop 6 (connecting strands F and G) in C H 1 with antigenic peptides that contain T-cell epitopes. Such molecules have further been equipped with variable (V) regions that confer specificity to surface molecules on APCs, such as IgD, MHC class II and CD14 (Lunde et al., 1999; Rasmussen et al., 2001; Lunde et al., 2002; Schjetne et al., 2005; Tunheim et al., 2005) . The final rAb targets the integrated T-cell epitope to the antigen-processing compartment of APCs, where the epitope is excised from the rAb, bound to MHC class II and transported to the cell surface for presentation to CD4 þ T-cells. This targeting strategy has generally increased the efficiency of T-cell stimulation four to five logs compared with synthetic peptides, on a molar basis. In each rAb we have previously introduced a single T-cell epitope derived from either the light (L) chain of the myeloma protein M315 (aa 91-101, l2 with a model epitope derived from l2 315 (aa 89-105). Eight loop positions were identified that could hold the inserted T-cell epitope while maintaining rAb secretion, binding to IgD on B cell APCs and ability to enhance stimulation of T-cells (Flobakk et al., 2008) . Here we have selected four of those eight loops which were identified as useful for peptide insertion, namely loop 6 in C H 1, loop1 and loop 6 in C H 2 and loop 6 in C H 3. These loops were substituted with the peptides described above, derived from OVA, HA, HEL as well as aa 89-105 l2
315
, and mutants were made that held one, two or more foreign peptide sequences. We found that mutants with one peptide in C H 1 in combination with two in C H 2 were secreted from producing cells and bound IgD. When mixed with irradiated spleen cells and specific T-cells in vitro, activation of T-cells with any of the three specificities was observed. We then constructed similar plasmids encoding recombinant antibodies (rAbs) with anti-CD40 specificity. The plasmids were given as DNA vaccines to sets of mice that raised specific T-cell responses.
Materials and methods

Production of mutant rAb
The gene encoding a G3m (b0) variant (Huck et al., 1986) , a gift from Dr M. P. LeFranc (IMGT, France), was template in all mutagenesis reactions, and the complete mutant H chains were assembled in the expression vector pLNOH2 IgD . Expression vectors pLNOK IgD and pLNOH2 IgD , which encode mouse IgD (mIgD) specific L and H chains, respectively, have been described (Lunde et al., 1999) . Vectors encoding human IgG3 (hIgG3) H chain genes with aa 323 -339 from OVA substituted with loop 6 C H 1 or l2 315 in loop 1 C H 2 and loop 6 C H 3 have been described (Rasmussen et al., 2001; Flobakk et al., 2008) . Loop 1 in C H 2 was substituted with nucleotide (nt) encoding aa110 -120 from HA by QuikChange mutagenesis (Stratagene). A silent SspI site was introduced for the identification of plasmids harbouring the mutation. Loop 6 in C H 2 was substituted with aa 46-61 from HEL by polymerase chain reaction SOEing. Primers are presented in Table I . Screening for mutants was performed with the HEL specific primer HELdir and the primer CH2rev. Genes encoding multiple epitopes were constructed by subcloning using restriction sites AgeI, BglII, BmgBI, BstEII, BtgZI, HindIII, PmlI and SacII (Fig. 1B) . All mutant H chain genes assembled in pLNOH2 IgD were co-transfected with pLNOK IgD in 293E cells as described (Berntzen et al., 2005) . The cloning of V region genes that confer specificity for mouse CD40 (mCD40) has been described (Schjetne et al., 2007) . The mutant H chain genes were assembled in pLNOH2 CD40 and co-transfected with pLNOK CD40 in 293E cells. Supernatants were harvested as described (Berntzen et al., 2005) .
Ammonium sulphate precipitation
Protein in supernatants was precipitated by a 1 : 1 addition of a saturated ammonium sulphate solution. After 20 min room temperature (RT) incubation, the precipitates were centrifuged at 20 000 g for 10 min. Pellets were dissolved in 2 ml dH 2 O and dialysed three times with phosphate-buffered saline (PBS) and twice with fresh cell culture media at 48C.
Antibodies
The mAb HP-6050 (Sigma-Aldrich) is specific for the hIgG3 hinge. The two mAbs 132c8-bio and HP-6050 were compared for binding to all four human IgG isotypes side by side in enzyme-linked immunosorbent assay (ELISA), and found to bind hIgG3 hinge in a similar fashion. Sheep polyclonal Ab s303 is specific for human IgG Fab and has been described (Aaberge et al., 1992) . Soluble mIgD was produced as described (Loset et al., 2004) . Recombinant mCD40/Fc Ig chimeric protein was obtained from R&D Systems. 
Analysis of secreted rAb by sandwich ELISA
Microtiter plates were coated with human IgG Fab specific Ab s303 (2 mg/ml), soluble mIgD (4 mg/ml), 5-iodo-4-hydroxy-3-nitrophenactetyl conjugated bovine serum albumin (BSA-NIP) (1 mg/ml) or mCD40/Ig (4 mg/ml). Supernatants were applied to each well and detected with hIgG3 hinge-specific mAb 132c8-bio (1 : 8000) or anti-hIgG3-bio (clone HP6050, Sigma).
Western blot
rAb samples were separated on Criterion XT Precast Gels (Bio-Rad) and blotted onto an Immobilon TM -p polyvinylidene difluoride membrane (Sigma-Aldrich) at 20 V for 30 min. Membranes were probed with biotinylated mouse ahIgG3 (HP-6050) (Sigma-Aldrich), horseradish peroxidaseconjugated streptavidin (GE Healthcare) and ECL Plus Western Blotting Detection Reagents kit (GE Healthcare), and were analysed using the software ImageQuant TL v2003.02 (GE Healthcare). Individual Ab concentrations were normalized to a known concentration of purified hIgG3.
Cell lines and mice
DO11.10 OVA 323 -339 -specific T-cell receptor (TCR) transgenic mice on a BALB/c background (Murphy et al., 1990) , and the l2 315 -specific TCR transgenic mice on a BALB/c background (Bogen et al., 1992) have been described. BALB/c and C3H mice were from Taconic (Ry, Denmark). 
Peptides
OVA (323 -339) and HEL (46 -61) peptides were from GenScript (Piscataway, NJ, USA). A synthetic peptide corresponding to aa 89 -107 of l2 315 of the myeloma protein M315 was obtained from NeoMPS (Groupe SNPE, France).
In vitro T-cell proliferation assays
Samples of 5 Â 10 5 irradiated (2000 cGy) BALB/c spleen APC were cultured with 10 5 LN cells from DO11.10 mice or mice transgenic for T-cell receptors of the CD4 þ T-cell clone 4B2A1 (Bogen et al., 1992) and various amounts rAb and synthetic peptides in triplicates for 72 h. The cultures were then pulsed with 1 mCi [ 3 H]dThd for 16-24 h, harvested, and counted using the TopCount NXT scintillation counter (GMI, MN, USA). Detection of IL-2 in supernatants was performed in plates coated with JES6-1A12 (2 mg/ml). JES6-5H4 (1 mg/ml) was used as detection Ab for IL-2. Standard curves were prepared from a 2-fold dilution starting at 2 ng/ml of rIL-2 (BD Pharmingen).
Cytokine secretion assay
Portions of spleen cells from C3H mice (irradiated at 2000 cGy) 5 Â 10 5 per well and 3A9 hybridoma cells, 5 Â 10 4 cells per well, were added in triplicates. RAb and synthetic aa 46-61 HEL peptides were added in 5-fold series and the plates were incubated at 378C for 48 h. Supernatants were diluted 1 : 3, 1 : 30 and 1 : 300 and portions of 5 Â 10 3 CTLL-2 cells added to each well. A standard of IL-2 were included. After incubation at 378C for 20-24 h, 1 mCi [ 3 H]dThd was added followed by incubation, cell harvest and scoring as above.
DNA vaccination and electroporation
Plasmids were purified by EndoFree Qiagen kit (Germantown, MD, USA) and diluted in 0.9% NaCl. The DNA-solution (70 ml) was a mixture of four plasmids: 100 mg amCD40IgG-pLNOH 2 , 100 mg amCD40-pLNOk, 50 mg pUMVC1-mGM-CSF (Aldevron) and 50 mg mMIP-1a-pLNOH 2 . Immediately after injection, electroporation was performed by the use of the Elgen electroporator device equipped with a caliper electrode (Elgen, Inovio Biomedical Co., PA, USA). The settings were: bipolar pulses of 100 mV Â 0.2 ms with pulse sequence and pulse sequence train being 1000 and 10, respectively.
In an alternative protocol, DNA was delivered intradermally according to the procedure described by Roos et al. (2006) . The DNA-solution (28 ml) contained 28 mg encoding aCD40IgG-pLNOH 2 , 28mg aCD40-pLNOH 2 k, 14 mg pUMVC1-mGM-CSF and 14 mg mMIP-1a-pLNOH 2 . Immediately after injection, electrodes were placed over the injection site and voltage was applied (two pulses, 1125 V/cm, 50 msþ8 pulses, 275 V/cm, 10 ms). Electroporation was performed by the PA-4000S-Advanced PulseAgile Rectangular Wave Electroporation System (Cyto Pulse Sciences, Inc.).
Enzyme-linked immunospot assay
OVA-and HEL-specific cellular immune responses in vaccinated mice were assessed by IFNg-and IL-4-enzyme-linked immunospot (ELISPOT) assays. Multi-ScreenHTS-IP Filter Plates (Millipore) were pre-treated as suggested by the manufacturer. The plates were coated with 75 ml 11B11 (10 mg/ml) or AN-18 (10 mg/ml) for detection of IL-4 and IFNg, respectively. After incubation at 48C overnight, the plates were washed three times in 150 ml sterile PBS before adding splenocytes that were incubated together with OVA or HEL peptide at 378C for 26 h. After washing in PBS (3 Â 150 ml), adherent cells were lyzed by water before one wash with 150 ml PBS containing 0.01% Tween 20 and one wash in PBS. Biotinylated anti-IL-4 (75 ml, 1.5 mg/ml, BVD6-24G2, BD Pharmingen, San Jose, CA, USA) or anti-IFNg (1.5 mg/ml, XMG1.2) was added overnight (48C). Streptavidin conjugated with alkaline phosphatase (1 : 3000, Amersham Pharmacia Biotech, Amersham, UK) was added for 1 -2 h at RT before development of the spots by 5-bromo-4-chloroindol-3-yl phosphate/nitro blue tetrazolium buffer solution (Zymed, Carlsbad, CA, USA). Some experiments were performed using the The ELISpot PRO kit and The ELISpot PLUS kit from Mabtech (Mabtech AB, Sweden). The reaction was stopped by tap water and the plates were air dried before the number of spots was determined electronically by Zeiss KS-EliSpot-401 instrument.
Statistical analyses
Immune responses among groups of mice are presented as means with SEM. P values were calculated by use of the Ab with three epitopes two-tailed t test in GraphPad Prism version 4.03. P values ,0.05 were considered significant.
Results
Secretion of single-loop replacement rAb
Loops between b-strands in all three Ab C H domains can be replaced with the l2 315 T-cell epitope (Flobakk et al., 2008) . To study if other T-cell epitopes may be inserted, we replaced four different loops, namely loop 6 in C H 1, loops 1 and 6 in C H 2 as well as loop 6 in C H 3 with model epitopes from OVA, HA, HEL and l2
315
. Loop 6 C H 1 was replaced with OVA derived peptide, loops 1 and 6 C H 2 with HA and HEL peptides, respectively and loop 6 C H 3 with the l2 315 epitope ( Figs 1B and 2A ). Resulting rAbs with mIgD specificity were produced in 293E cells from expression vectors pLNOH2 (encoding H chain) and pLNOK (encoding L chain) as previously described (Berntzen et al., 2005) . The resulting rAb had the expected specificity as shown in ELISA (data not shown). Moreover, the indicated loops could be substituted with maintenance of secretion, albeit at levels reduced to 20-55% of wild type (wt) level (Fig. 2B) . Thus, all these T-cell epitopes may be introduced into the loops chosen in a single replacement format.
Secretion of multi-loop replacement rAb
We then constructed rAbs which carried combinations of two or three peptides from OVA, HA, HEL and l2 315 simultaneously substituted in loops 6 C H 1, 1 C H 2, 6 C H 2 and 6 C H 3.
Upon producing rAb transfectants, we found that rAbs with one epitope in C H 1 and a second in C H 2 or C H 3 were secreted, however at reduced levels at 15% compared with wt. This also applied to a rAb with two epitopes in C H 2, and one with three epitopes; one in C H 1 and two in C H 2. Neither of five rAb with epitopes in both C H 2 and C H 3 was secreted (Fig. 2B) .
To rule out that the different aa sequences of the four T-cell epitopes chosen were responsible for the effects seen, the experiment was repeated for double-and triple-peptide rAb that carried more than one copy of the l2 315 epitope in loop 6 C H 1, 6 C H 2 and 6 C H 3. Again, rAbs with one epitope in C H 1 and a second in either C H 2 or C H 3 were secreted (10 -20% of wt), while rAbs with epitope in both C H 2 and C H 3 were not. Furthermore, a mutant with the l2 315 peptide in both loops 1 and 6 of C H 2 was tested, and found to be secreted at the same level as the rAb with HA and HEL epitopes in these loops (Fig. 2C) . Based on these results, we excluded replacement of loop 6 C H 3 from our multi-vaccine design, and focused our work on a triply substituted rAb with OVA in loop 6 C H 1, l2 315 in loop 1 C H 2 and HEL in loop 6 C H 2. This, as well as a second, similarly substituted triple mutant rAb with OVA, HA and HEL was secreted at a level of 15% of wt (Fig. 2B) .
Triple-epitope rAb stimulate specific T-cells with efficiencies similar to that of single-peptide rAb Supernatants from cells producing rAbs were ammonium sulphate precipitated and dialysed in fresh medium, as described in Materials and methods (Berntzen et al., 2005) . Samples were then run on sodium dodecyl sulfate polyacrylamide gel electrophoresis and western blotted to demonstrate that all rAbs had the correct mass of 165 kDa and thus consisted of disulfide linked H and L chains, H 2 L 2 (Fig. 2D) . The final 
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concentrations of rAbs were adjusted according to the results from the ELISAs and the western blot, to ensure that close to identical amounts of rAbs were tested in T-cell proliferation assays.
To detect rAb-induced T-cell proliferation, LN T-cells from DO11.10 TCR transgenic mice were used. (Fig. 3) .
The dose -response curves (Fig. 3A-C) illustrate that triple-epitope Abs are equal or better than single-epitope rAbs in their ability to stimulate specific T-cells. These results indicate that the loading of an Ab with multiple immunogenic peptides is feasible, and that peptide excision, presentation and the subsequent T-cell activation induced by the individual peptides is not reduced by the presence of the additional epitope substitutions.
Mouse CD40-specific rAbs enhance in vitro proliferation of antigen-specific CD4 þ T-cells
The above experiments were designed for testing of multiple loop replacements in vitro. To prepare for in vivo studies, the mIgD-specific V regions were replaced with V regions conferring anti-mCD40 specificity and rAbs were successfully produced as above (Rolink et al., 1996; Schjetne et al., 2007) . Specificity was demonstrated using recombinant mCD40/ Fc chimeric Ab or BSA-NIP as antigens in ELISA. As shown in Fig. 4A , all the anti-mCD40 rAbs bound to the capture Ab, but not to control BSA-NIP. The converse was true for anti-NIP rAb used as non-targeted control in the cellular assays (see below).
In a first set of experiments, we compared the ability of mCD40 specific rAbs and non-targeted rAbs with OVA peptide in loop 6 C H 1 to induce in vitro T-cell proliferation. BALB/c spleen cells were used as APCs and LN cells from DO11.10 mice as responder cells. As illustrated by the dose -response curves in Fig. 4B , the mCD40 targeted rAbs were .10 3 more efficient than the non-targeted control.
Targeting of single-and triple-peptide containing rAb to mCD40 induces an antigen-specific Th1 response in mice
Given the finding that the rAbs stimulated specific T-cells in vitro (Fig. 4) , we wanted to investigate whether they could induce antigen-specific T-cell responses in vivo. We have previously shown that CD40-specific proteins with the l2 315 epitope induce T-cell responses (Schjetne et al., 2007) . As l2 315 may be considered a relatively weak T-cell antigen (Bogen et al., 1986) , the response elicited in normal mice was minimal. With mice adoptively transferred with LN-cells from l2 315 -specific transgenic mice, the proliferative responses of specific T-cells were high (Schjetne et al., 2007) . In the present study, we examined responses of nontransgenic OVA-and HEL-specific CD4
þ T-cells in normal mice.
We took advantage of the finding that injection of DNA L and H chain encoding genes, combined with electroporation, results in secretion of functional Abs (Tjelle et al., 2004) . Both single-and triple-epitope mCD40-specific rAbs were delivered as DNA into the muscle (i.m.) or into the dermis (i.d.). Plasmids encoding mGM-CSF and mMIP-1a were delivered together with the rAbs in each case in order to recruit APC and promote maturation (McKay et al., 2004) . C3H mice were immunized i.m. with plasmids encoding anti-mCD40 rAb with single (HEL) or triple (OVA-l-HEL) peptides. Splenocytes were harvested after 19 days, and responded, however, weakly, to HEL peptide. A mixed Th1/ Th2 response was observed as the single-and triple-peptide rAb enhanced the number of HEL-specific IFNg-and IL-4-producing T-cells (Fig. 5A and data not shown) . Plasmids encoding mGM-CSF and mMIP-1a or NaCl did not elicit specific T-cell responses following i.m. delivery in BALB/c (data not shown). In another set of experiments, BALB/c mice were immunized i.d. with plasmids encoding anti-mCD40 rAb containing single (OVA) or triple (HEL-l-OVA) epitopes and splenocytes and lymph node cells were harvested after 21 days. Mice given NaCl and mice given mGM-CSF and mMIP-1a did not show peptidespecific responses. By contrast, plasmids encoding anti-mCD40 rAb containing single (OVA) or triple (HEL-l-OVA) elicited significant peptide-specific Th1 responses (Fig. 5B) . The results taken together suggest that the Ab format can be utilized for delivery of single-and triple epitopes and induce antigen-specific responses in vivo.
Discussion
We have previously constructed APC-specific rAbs, so-called 'Troybodies', with single T-cell epitopes replacing loops between b-strands in their C H domains. For vaccination purposes, however, it is often desirable to generate a broad immune response induced by several different sequences. This could be achieved by the production and use of mixes of rAb that carry different foreign sequences, or by the design of rAb that carry more than one foreign sequence. The latter approach would avoid competition for the target on APC and would be a more simple vaccine formulation. We have therefore explored this possibility.
We have recently shown that many but not all loops in all three C H domains can be substituted with the aa 89-105 l2 315 T-cell epitope, with maintenance of Ab secretion from producing cells and presentation of the grafted T-cell epitope after processing in targeted APC (Flobakk et al., 2008) . More specifically, from a total of 18 different rAb, 8 were both secreted well and found to induce T-cell activation. These had the peptide in either of loops 6 C H 1, all in C H 2 or 6 C H 3. Introduction of multiple epitopes, either in different units (Fab or Fc), different domains or within the same domain, would greatly benefit vaccine design, but could adversely affect Ab stability and rAb secretion from producing cells as well as intracellular processing. To test the feasibility of multi-epitope insertion into a single IgG, we selected four loops, namely loop 6 in all three C H domains as well as loop 1 in C H 2 for substitution with four different T-cell epitopes, l2 315 , HA, HEL and OVA. The four chosen loops are solvent exposed, located towards the outer edge of their respective domains, and do not participate in interdomain interactions. Moreover, these four loops tolerated single insertion of the l2 315 peptide as judged by secretion of rAb. We substituted loop 6 C H 1 with the OVA peptide, loop 1 C H 2 with the HA peptide and loop 6 C H 2 with the HEL peptide. Secretion of all these singly substituted rAb by transfectants was compared with that of wt IgG, and all were secreted, but less efficiently than the wt. This is consistent with previous findings, where the l2 315 peptide was substituted in the same locations (Flobakk et al., 2008) . The l2 315 peptide in its original position is a complementarydetermining region loop flanked by b-strands, the OVA peptide is mostly a b-ladder (Stein et al., 1991) , the HEL peptide in its native position has three turns and two b-strands (Maenaka et al., 1995) , while the HA peptide has an unknown structure. Compared with the l2 315 peptide, either of the latter non-Ab peptides most likely introduces stronger tension on the domain structure, which might reduce stability and affect secretion of whole rAb. However, level of secretion seems to be more influenced by localization of loop replacement than by the sequence of the epitope.
As for the feasibility of multi-epitope insertions into a single rAb, several conclusions can be made. First, 6 C H 3 loop replacement was poorly compatible with simultaneous loop replacements in C H 2 (Table II) . A reason for this might be that the two chains of the Fc fragment are connected through a conserved C H 3-C H 3 interface (Dall'Acqua et al., 1998) , and the accumulated tension caused by multiple loop substitutions most likely disrupts the C H 3-C H 3 interface. Thus, we avoided C H 3 insertions in our multi-epitope rAb. Second, the destabilizing effect of the substitutions was additive, even if the peptides were located in different domains and different parts, such as Fab (C H 1) and Fc (C H 2 and C H 3). This rule of thumb seems general and not dependent on specific peptide sequences used for loop replacements. Thus, we produced secretion competent rAbs that carried three epitopes, one in the Fab fragment, and two in C H 2 in the Fc fragment.
For APC targeting and peptide loading purposes, target cell killing should be avoided, and lack of Ab effector functions might well be an advantage. Interesting in this respect, is the fact that rAbs with single epitopes in either loop of C H 2 do not bind FcgRIIA (15). We here find that the C H 2 domain has the potential to carry at least two peptides, which could to a large extent abrogate effector functions of rAb such as complement activation and antibody-dependent cell cytoxicity.
For a rAb loaded with multiple antigenic peptides to be beneficial as a vaccine reagent, every loaded peptide should be presented by APC from its position within the APC-specific rAb. Therefore, we performed T-cell proliferation assays to evaluate whether and to what extent the triplepeptide rAb induced activation of specific T-cells. The results were compared with those obtained for three singly substituted peptide rAb. We found that all three peptides within the same multi-epitope rAb were presented to T-cells and induced T-cell activation at least as efficiently as did single-epitope rAb. It should be noted that IgD-targeting of singly substituted rAbs enhanced presentation Â10 3 compared with non-targeted NIP-specific equivalents (Lunde et al., 1999; Rasmussen et al., 2001) . As IgD-specific multiand singly substituted rAb had similar dose -response curves, an enhancement of T-cell responses by 10 3 , obtained by targeting to IgD, is likely, also for the multi-epitope rAbs. These results showed that multi-insertion does not diminish the presentation of each epitope, which is important for vaccine design.
The target molecule on the APC must be internalized for efficient processing, peptide loading and presentation to specific T-cells. Furthermore, binding should preferably induce maturation of the target APC. The rAb used in the present in vitro assays are specific for IgD on mouse B-cells. Although targeting to this receptor in vitro induces strong T-cell responses, IgD is not an optimal target in vivo. However, the discovery of Ag uptake receptors on DCs, such as DEC-205, DC-SIGN, CD40 and others (reviewed in Tacken et al., 2007) , has enabled the engineering of anti-receptor rAbs which specifically target DCs. Here we chose CD40 as target in in vivo studies. CD40 is a co-stimulatory molecule which belongs to the tumour necrosis factor receptor family and is expressed on many cells including monocytes, DCs, epithelial cells and endothelial cells (van Kooten and Banchereau, 2000) . On DCs, the ligation of CD40 induces cellular maturation and activation as manifested by increased surface expression of co-stimulatory and MHC molecules, production of pro-inflammatory cytokines such as IL-12 and enhanced T-cell activation (Cella et al., 1996) . We produced a series of plasmids with genes encoding CD40-specific single-and triple-peptide loaded rAbs. The rAbs were tested in in vitro assays, and we found that targeting of rAb to CD40 on APCs increased T-cell responses by .10 3 compared with nontargeted (NIP-specific) controls.
The plasmids were then delivered to two different mouse strains, BALB/c and C3H as naked DNA. Delivery of the DNA vaccines into mice caused weak CD4 þ T-cell responses, which nevertheless could be detected by ELISPOT assays. Future experiments will unravel how the responses may be enhanced.
